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Abstract 
The polygenic nature of essential hypertension and its dependence on environmental factors 
pose a challenge for biomedical research. We hypothesized that the analysis of gene ex-
pression profiles from peripheral blood cells would distinguish patients with hypertension 
from normotensives. In order to test this, total RNA from peripheral blood cells was isolated. 
RNA was reversed-transcribed and labeled and gene expression analyzed using significance 
Analysis Microarrays (Stanford University, CA, USA). Briefly, Significance Analysis Microar-
rays (SAM) thresholding identified 31 up-regulated and 18 down-regulated genes with fold 
changes of ≥2 or≤0.5 and q-value ≤5 % in expression. Statistically significantly gene ontology 
(GO) function and biological process differentially expressed in essential hypertension were 
MHC class II receptor activity and immune response respectively. Biological pathway analysis 
identified  several  related  pathways  which  are  associated  with  immune/inflammatory  re-
sponses. Quantitative Real- Time RT-PCR results were consistent with the microarray re-
sults. The levels of C - reactive protein were higher in hypertensive patients than normo-
tensives and inflammation-related genes were increased as well. In conclusion, genes enriched 
for “immune/inflammatory responses” may be associated with essential hypertension. In ad-
dition, there is a correlation between systemic inflammation and hypertension. It is anticipated 
that these findings may provide accurate and efficient strategies for prevention, diagnosis and 
control of this disorder. 
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INTRODUCTION 
It has become fairly obvious that hypertension is 
an escalating clinical and public health problem for 
both developed and developing countries. According 
to recent report, as of the year 2000, 972 million people 
were afflicted worldwide and this figure is believed to 
rise to more than 1.56 billion by the year 2025 (1,2). 
Human essential hypertension enhances the risk of a 
variety  of  adverse  sequelae,  including  stroke,  heart 
failure, coronary heart disease and renal failure (3). 
Essential  hypertension  has  been  recognized  as  a 
complex,  multifactorial,  polygenic  trait  which  in-
volves multiple modulating genes and environmental Int. J. Med. Sci. 2011, 8 
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factors.  To  all  appearances,  identifying  genes  in-
volved in polygenic trait is much more difficult than 
monogenic  trait.  This  is  because  of  the  weak  rela-
tionship  between  allelic  variation  of  individual  loci 
and phenotypic expression of the trait. 
Interestingly, with the advent of molecular ge-
netics, substantial progress has been made in the last 
decade towards detection of genes involved in essen-
tial  hypertension  using  two  principal  techniques: 
linkage analysis and exploration of candidate genes. 
Unfortunately, these traditional techniques are inevi-
tably limited in that they normally allow researchers 
to study barely one or a few genes simultaneously. 
However, recent advances in molecular biology and 
technology have made it feasible to quantify the ex-
pression levels of thousands of genes simultaneously 
by utilizing the microarray technology. 
Microarray  technology  is  a  robust 
high-throughput method  use for efficient and accu-
rate simultaneous expression measurement of thou-
sands  of  genes  (4,  5,  6,  7).  The  use  of  microarray 
technology  for  gene  expression  profiling  has  been 
successful  and  increasingly  popular  particularly  in 
genetics and cancer research.  
There  is  an  extensive  body  of  clinical  and  ex-
perimental evidence that inflammatory processes are 
important participants in both the initiation and de-
velopment  of  hypertension  (8).  An  evidence  to  this 
report  is  the  elevated  levels  of  proinflammatory 
markers  such  as  Tumor  necrosis  factor-α  (TNF-α), 
Interleukin-6 (IL-6) and C-reactive protein observed 
in individuals with hypertensive (9). Blood leukocytes 
are  the  predominant  cells  that  provide  immunity, 
mediate stress and inflammation, and generate cyto-
kines, chemokines and growth factors that exepend 
important pathological and physiological actions on 
peripheral tissues. In that event, dissecting peripheral 
blood  cells  gene  expression  patterns  of  individuals 
with hypertension could reflect the potential markers 
of  the  disease,  including  inflammatory  response 
which is an important causal pathway leading to hy-
pertension. Not to mention, because of its handiness 
in  clinical  settings  and  fascinating  roles  in  immune 
and metabolism, and its direct contact with the dis-
eased vascular wall, peripheral blood may be the most 
practicable tissue type for gene expression profiling. 
We hypothesize that analysis of gene expression pro-
files  from  peripheral  blood  cells  would  distinguish 
patients with hypertension from normotensives. The 
purpose  of  this  novel  project  is  to  use  peripheral 
blood cells as a surrogate tissue to distinguish patients 
with human essential  hypertension from  normoten-
sives by gene expression profiling. Accordingly, it is 
hoped that understanding the genetic determinants of 
hypertension  will  contribute  to  improvements  in 
prevention, diagnosis and treatment of this disorder. 
MATERIALS AND METHODS 
Ethics Statement 
Ethical  approval  for  the  study  was  obtained 
from the Medical Faculty of China-Japan Union Hos-
pital  of  Jilin  University,  China.  All  study  subjects 
provided written informed consent for the collection 
of samples and subsequent analysis. This study was 
conducted according to the principles and guidelines 
expressed in the declaration of Helsinki. 
Study Subjects 
A total of 18 subjects (n=18) were recruited in 
this study; 9 hypertensives and 9 normotensives. In-
clusion criteria for the hypertension participants were 
average Systolic blood pressure (SBP) ≥ 160 mm Hg 
and Diastolic blood pressure (DBP) ≥ 100 mm Hg and 
absence of secondary hypertension. Inclusion criteria 
for  the  normotensives  were  SBP  <  135  mmHg  and 
DBP < 85 mm Hg and absence of family history of 
hypertension in first degree relatives. Exclusion crite-
ria  were  diabetes,  smoking,  renal  failure,  coronary 
artery disease (CAD), stroke, peripheral artery disease 
(PAD). The variables measured were age, sex, body 
mass index (BMI), SBP, DBP, creatinine, triglycerides, 
high  density  lipoprotein  Cholesterol  (HDL-C),  low 
density  lipoprotein  cholesterol  (LDL-C),  glucose 
(GLU),  and  high  sensitivity  C  -  reactive  protein 
(hs-CRP). 
C-reactive protein (CRP) Assay 
CRP was analyzed at the clinical chemistry la-
boratory  at  the  China-Japan  Union  Hospital,  Jilin 
University,  China.  CRP  was  determined  by  using 
Beckman  Coulter-Immunochemistry  system 
IMMAGE 800 (Brea, California) following  manufac-
turer’s  protocol.  The  causal  mechanisms  partly  re-
sponsible for an increased risk of cardiovascular dis-
ease remain largely unknown. We determine whether 
blood pressure is associated with systemic inflamma-
tion which is a down pat risk factor for cardiovascular 
event.  
RNA processing and quantification. 
In this process, peripheral blood cells were col-
lected from each participant. For microarray studies, 
we  constructed  6  pools  of  3;  hypertension  (n=3)  vs 
normotensive (n=3) and for validation through quan-
titative RT-PCR, hypertension (n=9) vs normotensive 
(n=9). 
Total RNA was extracted using TRIzol Reagent 
(Invitrogen, USA) according to the method described Int. J. Med. Sci. 2011, 8 
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by  Chomczynski  and  Sacchi  (10)  and  consecutively 
purified  using  the  RNeasy  Mini  cleanup  kit 
(QIAGEN, USA) according to manufacturer’s proto-
col. 
RNA quantity and quality were determined us-
ing a NanoDrop Technologies ND -1000 spectropho-
tometer (NanoDrop, Wilmington, DE 19810 USA) and 
an  Agilent  2100  bioanalyzer  (Agilent  Technology, 
USA). Any RNA sample that degraded was excluded 
from the study. 
Microarray procedures 
Microarray study was performed at CapitalBio 
Corporation  (Beijing,  China)  using  Affymetrix 
GeneChip  Human  Genome  U133  Plus  2.0  Array 
(Affymetrix,  Santa  Clara,  CA,  USA.)  according  to 
manufacturer’s protocol. Total RNA (10 μg) was first 
reverse  transcribed  using  a  T7-Oligo  (dT)  Promoter 
Primer  in  the  first-strand  cDNA  synthesis  reaction. 
Following  RNase  H-mediated  second-strand  cDNA 
synthesis,  the  double-stranded  cDNA  was  purified 
and served as a template in the subsequent  in vitro 
transcription  (IVT)  reaction.  The  IVT  reaction  was 
carried out in the presence of T7 RNA Polymerase and 
a biotinylated nucleotide analog/ribonucleotide mix 
for  complementary  RNA  (cRNA)  amplification  and 
biotin labeling. The biotinylated cRNA targets were 
fragmented in 5×fragmentation Buffer provided with 
the GeneChip Sample Cleanup Module (Affymetrix) 
at 94°C for 35 min. In brief, 10μg of fragmented bio-
tin-labeled cRNA per replicate in hybridization mix-
ture was then hybridized to Human Genome Array 
from Affymetrix GeneChip and incubated overnight, 
set  to  45°C  in  Affymetrix  GeneChip  Hybridization 
Oven  640,  all  according  to  the  manufacturer’s  in-
structions.  After  16  hrs  of  hybridization  in  several 
cycles, the mixtures were then removed, chips were 
washed with Non-Stringent Wash Buffer and stained 
with Streptavidin Phycoerythrin (SAPE) and antibody 
solution mix (Affymetrix) on an automated Affymet-
rix  GeneChip  Fluidics  Wash  Station  450.  The  data 
were collected by using Affymetrix GeneChip Scanner 
3000 with workstation. Microarray images were pro-
cessed and raw data were extracted with Affymetrix 
GeneChip Operating Software (GCOS1.4).  
Quantitative Real-Time RT-PCR validation of 
microarray gene expression patterns 
To  confirm  the  microarray  data,  ten  differen-
tially expressed genes were chosen because of their 
different processes and perceived biological relevance 
to the disease. Six (CD36 molecule (thrombospondin 
receptor),  solute  carrier  family4  anion  exchanger 
member 1 (SLC4A1), neuroepithelial cell transforming 
1 (NET1), sestrin 3 (SESN3), zinc finger protein 652 
(ZNF652), peroxiredoxin 6 (PRDX6)) were selected for 
their  higher  expression  and  four  (Huntingtin  inter-
acting  protein  1(HIP1),  folate  receptor  3  (gamma) 
(FOLR3),  endoplasmic  reticulum  aminopeptide 
1(ERAP1), complement factor D (CFD)) for their low-
er expression. The primers set for the ten genes were 
designed using Primer3 (Table 1). Briefly, the synthe-
sized cDNA were subjected to qPCR and amplifica-
tions performed with BioEasy SYBR Green I (Biotechs, 
China). Specificity of all individual amplification re-
actions was confirmed by melting curve analysis. Re-
al-time  expression  values  were  calculated  by  using 
the relative standard curve method. Relative quanti-
fication method was chosen for each of the 10 genes in 
our study. Standard curves were generated for each 
mRNA by using 10-fold serial dilutions. All reactions 
were based on the following recommended protocol 
using  0.5µl  of  each  primer  and  1µl  of  template  per 
reaction.  
 
Table 1, Real-Time PCR Primers for validation of microarray data 
Gene 
Symbol 
RefSeq Tran-
script ID 
Forward Primers  Reverse Primers  Product size ( 
bp)  
Temp 
CD36  NM_000072  5'ATGGATTAAACCCAAATGAAGA 3’ 5'CCCAGTCTCATTAAGCCAAAG 3’  188  58℃ 
SLC4A1  NM_000342  5'GCTCCTATTTCCCTGGCAAG 3’  5'CCGAGAGTTTCTGGGTGTAGGT 3’  120  60℃ 
NET1  NM_001047160  5'TACAGTCATTTACCCTTCGTGG 3’  5'TTCACCTCGGGACATTTCAT 3’  200  60℃ 
SESN3  NM_144665  5'CAGGCAGCAACTTTGGGATT 3’  5'GACGCCTCTTCATCTTCCCT 3’  100  60℃ 
ZNF652  NM_001145365  5'CTGTGGAAAATCATTCAAACGC 3’  5'TTTCGTCACAGTTCTCGCATCTA3’  95  60℃ 
PRDX6  NM_004905  5'TCTATCCTCTACCCAGCTACCA 3’  5'TCCCCATCCTTCCAATCAA 3’  119  60℃ 
HIP1  NM_005338  5'CGGACTCAGACTGTCAGCATC 3’  5'TGGCAGAACTTCCAGCAGAG 3’  179  60℃ 
FOLR3  NM_000804 
 
5'TGTATGGCCAGTGCAGTCCC 3’  5'GCAGGTGGGTTCCATCTTAC 3’  131  60℃ 
ERAP1  NM_001040458  5'ATGCCATTGGTGAAATCTGTG 3’  5'CCACTCTTGGTTATCTTGCTGA 3’  137  60℃ 
CFD  NM_001928 
 
5'CTGCTACAGCTGTCGGAGAAG 3’  5'CGCGTGGTTGACTATGCC 3’  129  60℃ 
 Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
171 
 
Essentially,  reactions  were  accomplished  for 
each sample for 45 cycles/95℃/2min denaturing step; 
94℃/15  sec  annealing/extension  step  and  final  ex-
tension  step  at  60℃/40  sec  in  the  ABI  PRISM  7500 
Sequence  Detection  System  (Applied  Biosystems, 
USA). Data are reported as values normalized to the 
housekeeping  gene  GAPDH.  One-Way  ANOVA 
analysis  was  performed  using  SPSS  (13.0)  software. 
Significance  difference  between  the  means  for  each 
gene was evaluated using LSD or Tamhane’s T2 test 
(significance  levels  at  P  <  0.05).  All  values are  pre-
sented as means ± SEM. 
Data Analysis 
Participants’ demographics 
Participants’  demographics  were  recorded  and 
analyzed using the Statistical package for Social Sci-
ences (SPSS) for windows, version 12 (SPSS Inc., Chi-
cago, IL, USA). All clinical parameters, including CRP 
were compared by student t- test. The levels of CRP 
were compared between patients with hypertension 
and normotensives. 
Array Analysis 
The  data  were  analyzed  using  SAM;  Stanford 
University, CA, program (11).This method assigns a 
score to every gene on the basis of change  in  gene 
expression  relative  to  the  standard  deviation  of  re-
peated measurements. To estimate the false discovery 
rate (FDR), SAM uses permutations of the repeated 
measurements,  which  is  the  percentage  of  genes 
identified by chance. 
Basically, array normalization and computation 
of expression values of the 6 chips were performed by 
using  DNA-Chip  Analyzer  (dchip)  (12, 13).  For  an-
notation  of  the  resulting  genes,  the  gene  ontology 
browser  NetAffymetrix  (http://ww.affymetrix.com) 
was used (14). 
Similarly, the differentially expressed genes with 
≥2  or≤0.5  FC,  q-value  ≤5%  and  FDRs  of  5.0  or  less 
were analyzed using t test and P-value and clustered 
with the software package cluster 3.0.The genes were 
categorized  more  specifically  by  biological  process 
ontology terms and Kyoto Encyclopedia of Genes and 
Genomes  (KEGG)  biological  pathways  using  the 
software  Molecule  Annotation  System  2.0 
(http//:bioinfo.capitalbio.com/MAS/)  (capitolbio, 
Beijing, China).  
Gene Ontology Analysis 
The  differentially  expressed  genes  were  classi-
fied with gene ontology (GO) analysis according to 
their functions. In this process, we employed the Z 
scores transformation statistics to compute standard-
ized difference score for each gene grouping (15).  
RESULTS 
Participants’ characteristics 
Table  2  displays  clinical  characteristics  of  par-
ticipants. There were no significant age, gender and 
triglycerides differences between groups. There were 
significant  BMI,  LDL-C,  HDL-C  and  creatinine  dif-
ferences between groups. The levels of CRP were sig-
nificantly different between patients  with hyperten-
sion  and  normotensives  (Table  2).  CRP  levels  were 
significantly  higher  in  the  hypertensive  group  than 
the normotensives. 
 
Table 2, Clinical characteristics of participants  
Parameter  Hyperten-
sion 
 n =9 
Normoten-
sive 
n = 9 
t  P 
Age, y  50±4.7  49±3.8  0.496  0.626 
Gender, M/F  5/4  5/4  —  1.000
※ 
BMI, kg/m²  27±2  25±1  2.683  0.016 
SBP,mm Hg  177±6  120±5  21.89
4 
<0.00
1 
DBP, mm Hg  100±10  79±1  6.269  <0.00
1 
LDL-C, mmol/L  3.5±0.9  2.6±0.2  2.929  0.010 
HDL-C, mmol/L  1.26±0.1  1.48±0.27  2.292  0.036 
Triglycerides, 
mmol/L 
1.2±0.5  1.1±0.4  0.469  0.646 
Glucose, mmol/L  4.9±0.7  5.1± 0.2  0.824  0.422 
Creatinine , µmol/L    75±7  81±3  2.364  0.031 
CRP mg/L  3.15±0.27  0.93±0.16  21.22
1 
0.001 
※ Fisher’s exact test. Values are shown as means ﾱ SDs, unless oth-
erwise specified; ―n‖ represents the number of subjects. 
 
 
Microarray analysis 
Affymetrix  GeneChips  Human  Genome  U133 
Plus 2.0 arrays were used to compare the population 
of hypertensive patients with the population of nor-
motensives. From a total of 54681 tested probe sets, 
19033  (34.80%)  were  found  to  be  present  (detection 
P-value <0.05). The data from the microarray analysis, 
using FC ≥2 or≤0.5 and q-value ≤5 % in expression, 
resulted  in  31  up-regulated  and  18  down-regulated 
genes.  The  data  discussed  in  this  manuscript  have 
been deposited in National center for Biotechnology 
information’s (NCBI) Gene expression Omnibus (16) 
and  are  accessible  through  GEO  series  accession 
number  GSE24752  (http://www.ncbi.nlm.nih.gov/ 
geo/query/acc.cgi?acc=GSE24752). Int. J. Med. Sci. 2011, 8 
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Between  patients  with  hypertension  (n=9)  and 
normotensives  (n=9),  we  identified  49  differentially 
expressed genes: 31 up-regulated and 18 down regu-
lated (Table 3). In addition to the genes validated by 
quantitative  RT-PCR,  the  following  genes  (ABCA1, 
ABCG1, ACP1, HLA-DPB1 and HLA-DPB1) may be 
relevant  to  the  disease,  though  they  were  not  vali-
dated.  
 
Table 3, List of statistically significantly expressed genes. Unbold and bold:  up and down regulated genes, respectively. 
Probe Set ID  Gene Symbol  Gene Title  Score(d) *  Fold Change  q-value (%)# 
242673_at  UBE3C  Ubiquitin protein ligase E3C  1.88526  5.88082  107.371 
1559810_at  LOC642313  hypothetical LOC642313  1.694141054  5.667934932  107.3708967 
242197_x_at  CD36  CD36 molecule (thrombospondin receptor)  1.667673318  4.800305344  107.3708967 
223528_s_at  LOC731602 /// 
METT11D1 
similar to methyltransferase 11 domain containing 
1 isoform 2 /// methyltransferase 11 domain 
containing 1 
1.61409178  4.552732468  107.3708967 
205592_at  SLC4A1  solute carrier family 4, anion exchanger, member 1 
(erythrocyte membrane protein band 3, Diego 
blood group) 
1.792785531  3.966354548  107.3708967 
221491_x_at  HLA-DRB1 /// 
HLA-DRB3 /// 
HLA-DRB4 /// 
HLA-DRB5 /// 
LOC100133484 
/// 
LOC100133661 
/// LOC731718 
major histocompatibility complex, class II, DR beta 
1 /// major histocompatibility complex, class II, 
DR beta 3 /// major histocompatibility complex, 
class II, DR beta 4 /// major histocompatibility 
complex, class II, DR beta 5 /// similar to Major 
histocompatibility complex, class II, DR beta 4 /// 
similar to HLA class II histocompatibility antigen, 
DR-W53 beta chain /// similar to HLA class II 
histocompatibility antigen, DRB1-7 beta chain 
precursor (MHC class I antigen DRB1*7) (DR-7) 
(DR7) 
4.406126791  3.846374234  0 
201829_at  NET1  neuroepithelial cell transforming 1  1.55584681  3.691284279  107.3708967 
202918_s_at  MOBKL3  MOB1, Mps One Binder kinase activator-like 3 
(yeast) 
1.546033549  3.464079501  107.3708967 
1556988_s_at  CHD1L  chromodomain helicase DNA binding protein 
1-like 
1.783724855  3.393248908  107.3708967 
235684_s_at  SESN3  sestrin 3  1.805634293  3.390298507  107.3708967 
222103_at  ATF1  activating transcription factor 1  1.563370465  3.242605034  107.3708967 
212159_x_at  AP2A2  adaptor-related protein complex 2, alpha 2 subunit 1.679690033  2.941687252  107.3708967 
234989_at  NCRNA00084  non-protein coding RNA 84  1.827840917  2.770613352  107.3708967 
222418_s_at  TMEM43  transmembrane protein 43  3.166546718  2.735062637  107.3708967 
226338_at  TMEM55A  transmembrane protein 55A  1.618733749  2.640592116  107.3708967 
229713_at  PIP4K2A  Phosphatidylinositol-5-phosphate 4-kinase, type 
II, alpha 
2.5048  2.63686  107.371 
201863_at  FAM32A  family with sequence similarity 32, member A  1.55703607  2.583371779  107.3708967 
202838_at  FUCA1  fucosidase, alpha-L- 1, tissue  1.755214914  2.545112036  107.3708967 
205594_at  ZNF652  zinc finger protein 652  1.8699841  2.294553891  107.3708967 
213038_at  RNF19B  ring finger protein 19B  1.527459002  2.123070765  107.3708967 
204594_s_at  SMCR7L  Smith-Magenis syndrome chromosome region, 
candidate 7-like 
1.552814262  2.085802911  107.3708967 
205654_at  C4BPA  complement component 4 binding protein, alpha  2.720863469  2.035574937  107.3708967 
204838_s_at  MLH3  mutL homolog 3 (E. coli)  1.818566911  1.955759304  107.3708967 
201630_s_at  ACP1  acid phosphatase 1, soluble  1.598706621  1.944996865  107.3708967 
213872_at  C6orf62  Chromosome 6 open reading frame 62  1.803756915  1.927246979  107.3708967 
212473_s_at  MICAL2  microtubule associated monoxygenase, calponin 
and LIM domain containing 2 
2.117996134  1.812521326  107.3708967 
200844_s_at  PRDX6  peroxiredoxin 6  1.504701696  1.730976848  107.3708967 
214525_x_at  MLH3  mutL homolog 3 (E. coli)  1.632503504  1.697662053  107.3708967 
218676_s_at  PCTP  phosphatidylcholine transfer protein  1.666238817  1.622913043  107.3708967 
217902_s_at  HERC2  hect domain and RLD 2  1.807675847  1.620439623  107.3708967 
222730_s_at  ZDHHC2  zinc finger, DHHC-type containing 2  1.912364228  1.525083989  107.3708967 
209906_at  C3AR1  complement component 3a receptor 1  -1.678515094  0.661637838  107.40645 
201137_s_at  HLA-DPB1  major histocompatibility complex, class II, DP 
beta 1 
-1.526092306  0.650013114  107.40645 
244228_at  RABGAP1  RABGTPase activating protein 1  -1.58675  0.63685  107.406 
203504_s_at  ABCA1  ATP-binding cassette, sub-family A (ABC1), 
member 1 
-1.79577537  0.620203666  107.40645 Int. J. Med. Sci. 2011, 8 
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204861_s_at  NAIP  NLR family, apoptosis inhibitory protein  -1.628234316  0.616196823  107.40645 
236495_at  NAMPT  Nicotinamide phosphoribosyltransferase  -1.56998  0.61063  107.406 
204860_s_at  NAIP  NLR family, apoptosis inhibitory protein  -1.840825605  0.608945029  107.40645 
1557050_at  hoxa2  homeobox A2  -1.75782  0.5996  107.406 
204567_s_at  ABCG1  ATP-binding cassette, sub-family G (WHITE), 
member 1 
-1.766317544  0.575507906  107.40645 
226364_at  HIP1  Huntingtin interacting protein 1  -1.561453912  0.493465276  107.40645 
206371_at  FOLR3  folate receptor 3 (gamma)  -1.698220762  0.469677494  107.40645 
214012_at  ERAP1  endoplasmic reticulum aminopeptidase 1  -1.84135062  0.461242008  107.40645 
228642_at  hoax  homeobox A2   
-1.84056 
 
0.44361 
 
 
 107.406 
214012_at  HLA-DQA1 /// 
HLA-DQA2 
major histocompatibility complex, class II, DQ 
alpha 1 /// major histocompatibility complex, 
class II, DQ alpha 2 
-1.61069578  0.441730691  107.40645 
212671_s_at  TCL1A  T-cell leukemia/lymphoma 1A  -1.813983234  0.421260975  107.40645 
226736_at  CHURC1  Churchill domain containing 1  -1.53264385  0.416866185  107.40645 
1558048_at      -1.982  0.41038  107.408 
205382_at  CFD  Complement factor D (adipsin)  -1.817904316  0.378262489  107.40645 
* The student’s t-statistic value; #The lowest False Discovery Rate at which the gene is called significant 
 
Validation of microarray results by real-time 
quantitative RT- PCR analysis 
Ten genes were selected for further analysis and 
validation  of  microarray  results  using  quantitative 
RT-PCR. These include CD36, SLC4A1, NET1, SESN3, 
ZNF652 and PRDX6 (up-regulated) and HIP1, FOLR3, 
ERAP1 and CFD (down-regulated). The values were 
presented as means ± SEM (Table 2). SPSS analysis 
shows that the expression of CD36 (p., 0.000), SLC4A1 
(p.,  5.091e-005),  NET1  (p.,  3.56e-008),  SESN3  (p., 
1.181e-005), ZNF652 (p., 0.000), PRDX6 (p., 0.000) are 
up-regulated and HIP1 (p., 0.000), FOLR3 (p., 0.000), 
ERAP1  (p.,  0.004)  and  CFD  (p.,  0.006)  are 
down-regulated  (Fig.  1).  The  real-time  quantitative 
RT-PCR results were consistent with that of microar-
ray. 
Gene Ontology (GO) Analysis 
The  most  statistically  significantly  overrepre-
sented GO terms are displayed in Table (4) and sev-
eral  of  them  are  related  to  immune/inflammation 
responses.  Interestingly,  ―Major  histocompatibility 
complex  class  II  receptor  activity  (MHC),  Immune 
response  and  MHC  class  II  protein  complex‖  were 
identified  as  the  most  statistically  significantly  GO 
terms. These GO terms may play important role in the 
patho-biology of essential hypertension.  
 
 
Figure 1, Quantitative PCR measurements of gene expression of CD36, SLC4A1, NET1, SESN3, ZNF652, PRDX6, HIP1, 
FOLR3, ERAP1, and CFD from peripheral blood cells samples of patients with hypertension and normotensives. Significant 
levels at (p<0.05). Int. J. Med. Sci. 2011, 8 
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Figure 2, Results of Microarray Analysis: SAM Plot. Significant: 9060; Median number of false positives: 9731.02; False 
discovery rate (%): 107.41; Tail strength (%): -41.1; se (%): 29.2 
 
Table 4, statistically significantly overrepresented GO terms 
GO  GO TERM  Number of Genes in-
volved  
P-Valu
e 
Q-Valu
e 
Molecular 
Function 
MHC Class II receptor activity  2  0.0  0.0 
Cholesterol transporter activity  2  2.3E-5  4.1E-5 
Zinc ion binding  9  5.4E-5  5.8E-5 
Cholesterol binding  2  6.1E-5  6.1E-5 
Phospholipid transporter activity  2  2.05E-4  1.87E-4 
Toxin transporter activity  1  7.16E-4  4.4E-4 
Complement component C3a receptor activity  1  7.16E-4  4.4E-4 
Apolipoprotein A-1 receptor activity  1  7.16E-4  4.4E-4 
Glycoprotein Transporter activity  1  7.16E-4  4.4E-4 
C3a anaphylatoxin receptor activity  1  7.16E-4  4.4E-4 
Biological 
process 
Immune response  5  0.0  0.0 
Antigen processing & presentation of peptide or polysaccharide antigen via MHC 
class II 
3  0.0  0.0 
Phospholipid homeostasis  2  3.0E-6  7.0E-6 
Intracellular cholesterol transport  2  5.0E-6  1.0E-5 
Reverse cholesterol transport  2  1.8E-5  3.5E-5 
Phospholipid efflux  2  2.3E-5  4.1E-5 
Cholesterol efflux  2  4.0E-5  5.4E-5 
Positive regulation of lipid metabolism  2  1.52E-4  1.47E-4 
Foam cell differentiation  2  1.77E-4  1.68E-4 
Cholesterol metabolism  2  2.05E-1  1.87E-4 
Blood Pressure regulation  1  0.0537  0.01366
6 
Cellular 
Compo-
MHC class II protein complex  3  0.0  0.0 
Integral to plasma membrane  7  2.6E-5  4.1E-5 Int. J. Med. Sci. 2011, 8 
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nent  Integral to membrane  9  4.5E-5  5.4E-5 
Membrane  13  2.7E-4  2.22E-4 
Lysosome  3  3.16E-4  2.37E-4 
Golgi apparatus  5  3.65E-4  2.64E-4 
Nucleus  13  4.01E-4  2.69E-4 
Membrane Fraction  4  0.00117
6 
6.87E-4 
Plasma membrane  7  0.00139
2 
7.63E-4 
Phagocytic Vesicle  1  0.00357
7 
0.00161
8 
GO analysis was applied to differentially expressed genes. The number of transcripts calculated P-values and Q-values are shown. 
 
 
KEGG biological pathway  
Biological pathway analysis incriminated related 
pathways which were significantly modulated across 
patients with hypertension vs. normotensives. Several 
immune-related  pathways  were  significantly 
overrepresented  which  provides  evidence  that  im-
mune/inflammatory  responses  may  be  associated 
with  hypertension,  including  Cell  adhesions  mole-
cules, Systemic lupus erythematosus, Hematopoietic 
cell lineage, Asthma, Graft-versus-host disease, Allo-
graft rejection, Autoimmune thyroid disease, Antigen 
processing and presentation, Type 1 diabetes mellitus, 
and Complement and coagulation cascades. 
DISCUSSION 
In  this  study,  we  have  successfully  used  gene 
expression profiling in peripheral blood cells to iden-
tify differences in transcription profile of human es-
sential  hypertension  compared  with  normotensives. 
We chose to profile the blood in hypertensive patients 
because it is a sample that reflects ongoing pathologic 
processes  such  as  inflammation  and  structural  ab-
normalities.  And  therefore,  inflammatory-related 
genes were expected to be modulated in our experi-
ment. 
In regards to limitation of the study, our sample 
size is relatively small due to the significant costs in-
volved  in  microarray  experiment.  In  addition,  the 
microarray  technology  has  decreased  sensitivity  to 
detect low-abundance genes. In spite of these limita-
tions, our study reveals novel features of human es-
sential hypertension. 
Firstly, we investigated differences in transcrip-
tion  profile  of  human  essential  hypertension  com-
pared  with  normotensives.  We  identified  31 
up-regulated  genes  and  18  down-regulated  genes 
with FC of ≥2 or≤0.5 and q-value ≤5 % in expression. 
These  genes  and  GO  categories  identified  as  being 
differentially  expressed  in  essential  hypertension 
versus normotensives may be of significant biological 
interest. To the best of our knowledge, this is the first 
time  several  of  these  genes  become  candidates  for 
further  investigation  in  their  role  in  hypertension. 
Through quantitative RT-PCR, we confirmed the ex-
pression  of  10  (CD36,  SLC4A1,  NET1,  SESN3, 
ZNF652, PRDX6, HIP1, FOLR3, ERAP1 and CFD) out 
of the 49 differentially expressed genes. ERAP1 was 
previously shown to be an important player in hy-
pertension.  ERAP1  functions  in  several  biological 
networks such as regulation of blood pressure, angi-
ogenesis and presentation of antigens to MHC class I 
(17, 18, 19) as well as immune and inflammatory re-
sponses  (20).  A  possible  role  of  ERAP1  in  blood 
pressure regulation may be through its inactivation of 
angiotensin  II  and/or  generation  of  bradykinin  (17, 
20).  
CD36 is a scavenger receptor expressed in mac-
rophages, endothelial cells, denditic cells and in tis-
sues such as muscle, heart and fat (21, 22). Increasing 
evidence underscores the potential role of CD36 in the 
pathogenesis  of  hypertension.  One  possibility  is 
through the regulatory effect of endothelin-1 on CD36 
which might alter the properties of vascular smooth 
muscle  cells  (VSMCs),  thus  leading  to  the  develop-
ment  of  hypertension  and  atherosclerosis  (23). 
Pravenec and Kurtz demonstrated that deficiency in 
renal expression of CD36 could promote increase in 
blood pressure (24). 
The human anion exchanger 1 (AEI or SLC4A1) 
gene is a 911-residue glycoprotein that encodes pro-
tein in erythrocytes and basolateral surface of the al-
pha-intercalated cell in the collecting duct of the kid-
ney (25, 26). Intriguingly, this gene is a possible can-
didate for essential hypertension as its encoded pro-
tein does not  only function as chloride/bicarbonate 
exchanger but also in pathways that regulate blood 
pressure  (27).  Besides,  Kokubo  et  al.  (28)  reported 
association of SLC4A1 with both blood pressure vari-
ation and hypertension. Association between ZNF652 
gene and systolic or diastolic blood pressure and hy-
pertension  has  been  reported  elsewhere  (29,  30), 
however,  its  mechanistic  role(s)  were  not  defined. Int. J. Med. Sci. 2011, 8 
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NET1 and SESN3 have been suggested to be associ-
ated  with  genotoxic  stress  and  /or  oxidative  stress 
(31, 32, 33). Short while, oxidative stress has been im-
plicated in the pathophysiology of hypertension (34, 
35, 36). It is believed that an imbalance in superoxide 
and nitric oxide generation may lead to vasodilation 
and subsequently hypertension (Figure 3).  
 
 
 
Figure 3, Interconnections between Genes and their relationship to Hypertension. NO, indicates nitric oxide; AA, ara-
chidonic acid; ROS, reactive oxygen species; NFKB, nuclear factor-kappa B; NADPH, nicotinamide adenine dinucleotide 
phosphate.  
 
An increase in production of ROS enhanced de-
pletion of antioxidant (PRDX6) which may cause ox-
idant stress thereby leading to hypertension (37). The 
PRDX6 gene has also been implicated as a candidate 
gene for atherosclerosis (38). Seemingly, it has been 
proposed  that  HIP1  mutations  lead  to  abnormal 
hematopoiesis  (39)  and  Park&  Zambidis  (40)  have 
suggested a role of rennin-angiotensin system (RAS) 
in  hematopoiesis.  The  critical  physiological  roles  of 
RAS in blood pressure regulation could be a possible 
link  between  HIP1  and  hypertension.  FOLR3  has  a 
high affinity for folic acid and folic acid has been re-
ported to reduce serum homocysteine levels as well as 
systolic and diastolic blood pressure, in addition to 
improving the integrity of vascular endothelium (41, 
42). In the study of Gomez-Ambrosi et al. (43), FOLR3 
was differentially expressed in human omental adi-
pose tissue of obese individuals. The differential ex-
pression of this gene in both obese and hypertensive 
individuals demonstrate further evidence for a con-
sistent link between adiposity and hypertension. CFD 
is an immune/inflammatory-related gene involved in 
complement and coagulation cascades. Its role in hy-
pertension  biology  could  be  through  its  association 
with pathological angiogenesis. The excessive, insuf-
ficient or abnormal angiogenesis has been implicated 
in the pathogenesis of several cardiovascular diseases, 
including hypertension (44, 45). 
Other  modulated  genes  in  our  experiment, 
though  were  not  validated  by  quantitative  RT-PCR 
but  maybe  associated  with  and/or  play  role  in  hy-
pertension  include  ABCA1,  ABCG1,  ACP1, 
HLA-DPB1,  and  HLA-DRB3.  ATP  binding  cassette 
transporters (ABCA1, ABCG1) are important cellular Int. J. Med. Sci. 2011, 8 
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cholesterol  transporters/receptor  in  regulating  cho-
lesterol efflux. The implication of these genes as can-
didate genes for hypertension has been substantially 
catalogued (46, 47). ABCA1 mutations may increase 
the risks of both cardiovascular diseases and type 2 
diabetes by reducing plasma high density lipoprotein 
(48). However, their mechanistic roles in the patho-
genesis of essential hypertension remain irresolute.  
Acid  phosphate  1,  soluble  (ACP1)  has  been 
found  to  be  related  to  CAD  and  was  differentially 
expressed in human omental adipose tissue of obese 
individuals (49, 43). The up-regulation of ACP1 in our 
study  reinforces  the  notion  that  hypertension  is  in-
deed a disorder of cardiovascular endocrinology and 
metabolism.  Furthermore,  our  study  shows  that 
HLA-DPB1 and HLA-DRB3 may play important role 
in hypertension. Association of these genes with car-
diovascular, metabolic and immune diseases has been 
reported (50, 51, 52).  
Table 4 lists GO categories and specific number 
of  genes  with  their  respective  categories  that  were 
differentially expressed in peripheral blood samples 
of patients with hypertension compared with normo-
tensives.  The  ―MHC  class  II  receptor  activity‖  and 
―immune response‖ are intriguing and may be asso-
ciated with human essential hypertension.  
Biological  pathway  analysis  identified  several 
related  pathways.  The  overexpression  of  these  im-
mune-related pathways may show that hypertension 
may  be  associated  with  immune/inflammatory  re-
sponses. 
Secondly, we analyzed the levels of CRP in pa-
tients with hypertension by measuring CRP levels in 
participants included in the study. The levels of in-
flammatory marker, CRP were elevated in hyperten-
sive patients than the normotensives (Table 2). This 
finding which shows that inflammation is associated 
with hypertension is in concordant with many other 
studies (53, 54). Of note, inflammations in individuals 
with  hypertension  have  been  clearly  established, 
however, its contributory roles to the etiology of hy-
pertension  is  probably  secondary  to  hypertension. 
Endothelial dysfunction and angiotensin type 1 might 
be hypercritical in the development of hypertension. 
Recently,  several  studies  have  focused  on  endothe-
lium  and  angiotensin  molecular  networks  in  the 
pathogenesis  of  hypertension,  proposing  that  in-
flammation  is  associated  with  endothelium  damage 
and  the  RAS.  However,  these  questions,  ―Does  in-
flammation  lead  to  hypertension  or  does  hyperten-
sion induce inflammation?‖ necessitate further inves-
tigation.  
Taken  together,  this  study  has  demonstrated 
gene expression changes in peripheral blood cells that 
accurately distinguish patients with human essential 
hypertension  from  normotensives.  We  have  also 
identified a number of novel genes, GO categories and 
biological pathways that may be associated with the 
pathobiology  of  human  essential  hypertension. 
Moreover, our study has shown that inflammation is 
associated  with  hypertension.  It  is  anticipated  that 
understanding  the  genetic  background  of  essential 
hypertension  will  provide  accurate  and  efficient 
strategies for prevention, diagnosis and control. 
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